Normal-tension Glaucoma Management: A Survey of Glaucoma Sub-specialists in Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To investigate the current management patterns of glaucoma subspecialists with regard to normal-tension glaucoma(NTG) in Korea and to determine the effect of the two largest NTG trials on their clinical practice. Methods: A questionnaire survey was sent to glaucoma subspecialist members of the Korean Glaucoma Society. The questionnaireconcerned regular practice with respect to NTG and the extent to which it has been influenced by the CollaborativeNormal-tension Glaucoma Study and the Low-pressure Glaucoma Treatment Study (LoGTS). Results: A total of 134 glaucoma subspecialists completed the survey, with a response rate of 56%. The survey reported that88% and 78% of glaucoma subspecialists were familiar with the Collaborative Normal-tension Glaucoma Study and the LoGTS,respectively. With respect to mild or moderate NTG, most of the respondents (87%–91%) tended to treat their patientsimmediately without waiting for structural or functional progression. Among the respondents, 47 indicated that the LoGTSresults—according to which, 20% of the respondents tended to use brimonidine more often—affected their management. The first-choice topical drugs for NTG were prostaglandin analogues (76%), brimonidine (9%), beta-blockers (8%), and topicalcarbonic anhydrase inhibitor (6%). Conclusions: Regarding mild-to-moderate NTG, Korean glaucoma subspecialists tended to initiate treatment without waitingfor further progression. The impact of the LoGTS on NTG management was not dominant in clinical practice in Korea. Prostaglandinanalogs are the most frequently selected first-choice drugs for the management of NTG in Korea.
Abstract
Purpose: To investigate the current management patterns of glaucoma subspecialists with regard to normal-tension glaucoma(NTG) in Korea and to determine the effect of the two largest NTG trials on their clinical practice. Methods: A questionnaire survey was sent to glaucoma subspecialist members of the Korean Glaucoma Society. The questionnaireconcerned regular practice with respect to NTG and the extent to which it has been influenced by the CollaborativeNormal-tension Glaucoma Study and the Low-pressure Glaucoma Treatment Study (LoGTS). Results: A total of 134 glaucoma subspecialists completed the survey, with a response rate of 56%. The survey reported that88% and 78% of glaucoma subspecialists were familiar with the Collaborative Normal-tension Glaucoma Study and the LoGTS,respectively. With respect to mild or moderate NTG, most of the respondents (87%–91%) tended to treat their patientsimmediately without waiting for structural or functional progression. Among the respondents, 47 indicated that the LoGTSresults—according to which, 20% of the respondents tended to use brimonidine more often—affected their management. The first-choice topical drugs for NTG were prostaglandin analogues (76%), brimonidine (9%), beta-blockers (8%), and topicalcarbonic anhydrase inhibitor (6%). Conclusions: Regarding mild-to-moderate NTG, Korean glaucoma subspecialists tended to initiate treatment without waitingfor further progression. The impact of the LoGTS on NTG management was not dominant in clinical practice in Korea. Prostaglandinanalogs are the most frequently selected first-choice drugs for the management of NTG in Korea.
참고문헌 (25)
- Mitchell P, "Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study", Ophthalmology, 103, pp.1661~1669 (1996)
- Iwase A, "The prevalence of primary open-angle glaucoma in Japanese : the Tajimi Study", Ophthalmology, 111, pp.1641~1648 (2004)
- Kim CS, "Prevalence of primary open-angle glaucoma in central South Korea the Namil study", Ophthalmology, 118, pp.1024~1030 (2011)
- Anderson DR, "Collaborative normal tension glaucoma study", Curr Opin Ophthalmol, 14, pp.86~90 (2003)
- De Moraes CG, "Risk factors for visual field progression in the low-pressure glaucoma treatment study", Am J Ophthalmol, 154, pp.702~711 (2012)
- Krupin T, "A randomized trial of brimonidine versus timolol in preserving visual function : results from the Low-Pressure Glaucoma Treatment Study", Am J Ophthalmol, 151, pp.671~681 (2011)
- Kim CY, "Treatment patterns and medication adherence of patients with glaucoma in South Korea", Br J Ophthalmol, 101, pp.801~807 (2017)
- Symes RJ, "Normal tension glaucoma management : a survey of contemporary practice", Can J Ophthalmol, 52, pp.361~365 (2017)
- Cunningham CT, "Exploring physician specialist response rates to web-based surveys", BMC Med Res Methodol, 15, pp.32~ (2015)
- Heijl A, "Natural history of open-angle glaucoma", Ophthalmology, 116, pp.2271~2276 (2009)
- Anderson DR, "Collaborative Normal-Tension Glaucoma Study Group. Natural history of normal-tension glaucoma", Ophthalmology, 108, pp.247~253 (2001)
- Sawada A, "Progression to legal blindness in patients with normal tension glaucoma : hospital-based study", Invest Ophthalmol Vis Sci, 56, pp.3635~3641 (2015)
- Baek SU, "Risk factors for disease progression in low-teens normal-tension glaucoma", Br J Ophthalmol, 104, pp.81~86 (2020)
- Bengtsson B, "Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial", Ophthalmology, 114, pp.205~209 (2007)
- Caprioli J, "Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study", Ophthalmology, 115, pp.1123~1129 (2008)
- Liu CJ, "Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients", Ophthalmology, 109, pp.2241~2247 (2002)
- Tsumura T, "The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients", Clin Ophthalmol, 8, pp.1681~1687 (2014)
- Katz LJ, "Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group", Am J Ophthalmol, 127, pp.20~26 (1999)
- Blondeau P, "Allergic reactions to brimonidine in patients treated for glaucoma", Can J Ophthalmol, 37, pp.21~26 (2002)
- Schuman JS, "Clinical experience with brimonidine 0.2%and timolol 0.5% in glaucoma and ocular hypertension", Surv Ophthalmol, 41(Suppl 1), pp.S27~S37 (1996)
- 박은정, "녹내장에서 브리모니딘", 티몰롤 복합제제와 0.15% 브리모니딘 사용 시 알레르기 발생률의 비교, 2018, pp.59(5), 451~458[DOI]
- Acheampong AA, "Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits", Drug Metab Dispos, 23, pp.708~712 (1995)
- Patil PM, "Unequal accumulation of adrenergic drugs by pigmented and nonpigmented iris", Am J Ophthalmol, 78, pp.470~477 (1974)
- Kwon J, "Baseline systolic versus diastolic blood pressure dip and subsequent visual field progression in normal-tension glaucoma", Ophthalmology, 126, pp.967~979 (2019)
- Quaranta L, "Ginkgo biloba extract improves visual field damage in some patients affected by normal-tension glaucoma", Invest Ophthalmol Vis Sci, 55, pp.2417~ (2014)